ClinicalTrials.gg
RecruitingNCT05836831Updated Jan 22, 2026

Indian Trial of Tranexamic Acid in Spontaneous Intracerebral Haemorrhage

A Phase 4 interventional study of Tranexamic acid injection in Intracerebral Hemorrhagic Stroke, sponsored by Christian Medical College and Hospital, Ludhiana, India. Recruiting at 48 sites in India. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-01-22.

Sponsored by Christian Medical College and Hospital, Ludhiana, India · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Aug 2022, registered Apr 2023).
  • Started Aug 2022; still recruiting 4 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
3,400
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Study summary

This multicenter, pragmatic randomized, open-label clinical trial aims to assess whether Tranexamic Acid improves outcomes in adult patients with spontaneous intracerebral haemorrhage.

The participants presenting within 4.5 hours of the onset of symptoms of stroke with intracerebral haemorrhage confirmed on Computed Tomography (CT Scan) will be randomized into two groups in a 1:1 ratio using a central online randomization. The treatment arm will consist of giving intravenously 2 grams of Tranexamic Acid in 100 ml 0.9% sodium chloride administered over 45 minutes. Control arm patients will receive standard of care treatment as per the institutional protocol. In both arms, intensive systolic blood pressure reduction to less than 140 mmHg will be done using antihypertensive medications, which has to be achieved within one hour and will be maintained over next seven days. The choice of antihypertensive drug will depend on the clinician's preference.

Both groups will have a repeat CT scan after 24 hours to check for any increase in the haematoma volume. Any deterioration in the neurological status will warrant urgent brain imaging. On day 7, the patient will be assessed for their NIHSS score and mRS score. On day 90, quality of life and the functional outcome will be assessed.

Read the detailed description

Global Burden of Disease, Injury and Risk factors for hemorrhagic stroke 2010 estimated the burden of spontaneous intracranial haemorrhage (sICH) in India is profound (32 -49%) and it is associated with high mortality (up to 63 %) due to haematoma expansion which occurs in 38% of ICH within first few hours of presentation. Early administration of haemostatic drugs has been used in patients with trauma and was associated with improved outcomes. Similarly, if haemostatic drugs are administered early, which can be a simple and cost-effective intervention, may improve the functional outcomes in patients with sICH. Recently, the Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH 2 trial), which was done to see the effectiveness of the administration of tranexamic acid on hematoma expansion and functional outcomes at three months in patients who presented with sICH within 8 hours of presentation of symptoms onset, showed a decrease in haematoma expansion but no improvement in functional outcome at 90 days. Further larger randomized control trials are required to ascertain the effect of early administration of Tranexamic acid (TXA) in sICH. In India patients present to hospitals in the early stages that have developed symptoms after sICH and we propose to study the effect of intravenous Tranexamic Acid for hyperacute primary intracerebral haemorrhage within 4.5 hours of sICH.

Trial Population:

This multi-centric study will be conducted at 50 stroke centres in India associated with the INSTRuCT Network. All patients presenting with symptoms of stroke to the hospital and admitted to the stroke units will be screened for eligibility and if met, will be included in the study. The INTRINSIC trial intends to recruit 3400 patients.

Trial Design:

INTRINSIC Trial will be a multicenter, randomized, open-label, clinical trial. The participants will be randomized into two groups in a 1:1 ratio using a central database of INSTRuCT central online randomization. The baseline characteristics will be adjusted to stroke severity using the NIHSS score and the volume of haematoma. The treatment arm will consist of giving intravenously 2 grams of Tranexamic Acid in 100 ml sodium chloride 0.9 % administered over 45 minutes. Control arm patients will receive standard of care management as per the institutional protocol. Both groups will have a repeat CT scan after 24 hours to check for any increase in the haematoma volume. Any deterioration in the Glasgow Coma Scale (GCS) will warrant urgent brain CT scans. Antihypertensive drugs used and their doses to control BP will be recorded for up to 7 days. On day 7, the patient will be assessed for their NIHSS score and mRS score. On day 90, quality of life and the functional outcome will be assessed.

The need for this study:

The proportion of ICH is high in India and other LMIC's, particularly in Asia. Currently, there are no effective treatments available for sICH. Moreover, Tranexamic Acid is cheap, easily available and easy to administer.

02

Conditions studied

  • Intracerebral Hemorrhagic Stroke

Keywords

  • Stroke
  • Spontaneous Intracerebral Haemorrhage
  • Tranexamic acid
03

In context

Hemorrhagic Stroke

233 studies on the registry are indexed under Hemorrhagic Stroke; 93 are open to participants now.

This study's planned enrollment of 3,400 is above the median of 58 across 156 interventional studies indexed under Hemorrhagic Stroke.

Browse Hemorrhagic Stroke studies →

Lead sponsor

Christian Medical College and Hospital, Ludhiana, India is the lead sponsor of 12 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Adult patients aged more than 18 years, presenting with non- traumatic intracerebral haemorrhage within 4.5 hours of onset of stroke symptoms

Exclusion criteria

Exclusion Criteria:

  1. Patients with ICH secondary to anticoagulation, thrombolysis, or known underlying structural abnormality such as arteriovenous malformation, aneurysm, tumor, venous thrombosis or due to known hereditary coagulation disorders.
  2. to TXA.
  3. Concurrent participation in another trial.
  4. Pre-stroke \<3 months (e.g. advanced cancer).
  5. Glasgow coma scale (GCS) ⩽5.
  6. ICH secondary to trauma.
  7. Women of , pregnant, or breastfeeding at randomization.
  8. Geographical or other factors that prohibit follow-upto 90 days.
  9. Concurrent or planned treatment with any other hemostatic agents.
  10. ICH volume >60 mL as measured by ABC/2 method.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
3,400 participants (estimated)

Study arms

  • Experimental
    Intervention Arm

    The treatment arm will consist of giving intravenously 2 grams of Tranexamic Acid in 100 ml sodium chloride 0.9 % administered over 45 minutes. Intensive systolic blood pressure reduction to less than 140 mmHg will be done using antihypertensive agents (intravenous and/or oral) which is to be achieved within one hour and has to be maintained over seven days. BP monitoring is done every 15 minutes in the first hour and thereafter every hour for the next six hours after the initiation of intensive BP control. The choice of antihypertensive will depend on the clinician's preference.

    Drug: Tranexamic acid injection

  • No intervention
    Control Arm

    The control arm will receive a standard of care management as per the institutional practice. Intensive systolic blood pressure reduction to less than 140 mmHg will be done using antihypertensive (intravenous and/or oral) which is to be achieved within one hour and has to be maintained over seven days. BP monitoring is done for every 15 minutes in the first hour and thereafter every hour for the next six hours after the initiation of intensive BP control. The choice of antihypertensive will depend on the clinician's preference.

Interventions

  • The treatment arm will consist of giving intravenously 2 grams of Tranexamic Acid in 100 ml sodium chloride 0.9 % administered over 45 minutes.

    Also known as: Injection Pause 500 mg/5 ml, Injection Cyklokapron 500 mg/5 ml, Injection Trapic 500 mg/5 ml, Injection Tramix 500 mg/5 ml

06

What researchers measure

Primary outcomes

  1. Death

    Death at day 30. Absolute difference of 3% between intervention and control arm for the number of participants that expired at day 30

    Time frame: 30 days

Secondary outcomes

  1. Change in hematoma volume

    Radiological (CT scan): Change in hematoma volume from baseline to 24 hours scan, hematoma location and new infraction

    Time frame: 24 hours

  2. Neurological impairment

    Neurological impairment National Institutes of Health Stroke Scale (NIHSS) at day 7 (or discharge if sooner). Lower NIHSS indicates a good outcome.

    Time frame: 7 days

  3. modified Rankin Scale (mRS)

    Dependency using the seven-level modified Rankin Scale (mRS) at day 90. Good outcome is 0-2 and bad outcome is 3-6. Lower mRS indicated good outcome.

    Time frame: 90 days

  4. Quality of life EQ-5D

    Quality of life EuroQoL-5 dimension (EQ-5D) at day 90. Lover score indicates good outcome

    Time frame: 90 days

07

Study locations

45 of 48 sites recruiting
  • Government General Hospital
    Guntur, Andhra Pradesh 522001, India
    Recruiting
    • Sundarachary Nagarjunakonda, MD DM · Contactsundarachary@yahoo.com · 9440257675
    • Sundarachary Nagarjunakonda, MD DM · Principal investigator
  • Lalitha Super Specialty Hospital
    Guntur, Andhra Pradesh 522001, India
    Recruiting
    • Vijaya Pamidimukkala, MD DM · Contactdrvijayapvr@gmail.com · 9440808621
    • Vijaya Pamidimukkala, MD DM · Principal investigator
  • Dr Ramesh Cardiac and Multispecialty Hospital
    Guntur, Andhra Pradesh 522004, India
    Recruiting
    • Somasundaram Kumaravelu, MD DM · Contactneurovelu@gmail.com · 9553651777
    • Somasundaram Kumaravelu, MD DM · Principal investigator
  • Assam Medical College
    Dibrugarh, Assam 786001, India
    Recruiting
    • Binod Sarmah, MD DM · Contactb_sarmah2007@yahoo.com · 9577631327
    • Binod Sarmah, MD DM · Principal investigator
  • Guwahati Neurological Research Center
    Guwahati, Assam 781006, India
    Recruiting
  • Apollo Excelcare Hospitals
    Guwahati, Assam 781033, India
    Recruiting
    • Lakshya J Basumatary, MD DM · Contactdrbasumatary@gmail.com · 9954480668
    • Lakshya J Basumatary, MD DM · Principal investigator
  • Baptist Christian Hospital
    Tezpur, Assam 784001, India
    Recruiting
    • Jacob Johnson, MD · Contactcooljacky44@gmail.com · 7598626847
    • Jacob Johnson, MD · Principal investigator
  • Tezpur Medical College and Hospital
    Tezpur, Assam 784153, India
    Recruiting
  • Manipal Hospital
    Panjim, Goa 403004, India
    Not yet recruiting
    • Parul Dubey, MD DM · Contactdrdubeyparul@gmail.com · 9552530337
    • Parul Dubey, MD DM · Principal investigator
  • Shree Krishna Hospital Pramukhswami Medical College
    Anand, Gujarat 388325, India
    Recruiting
    • Soaham Desai, MD DM · Contactdrsoahamdesai@yahoo.com · 9979937885
    • Soaham Desai, MD DM · Principal investigator
  • Artemis Hospital
    Gurgaon, Haryana 122001, India
    Recruiting
    • Rajsrinivas Parthasarathy, MBBS MRCP · Contactrajsrinivasp@yahoo.co.in · 8826007421
    • Rajsrinivas Parthasarathy, MBBS MRCP · Principal investigator
  • All India Institute of Medical Sciences
    Bilāspur, Himachal Pradesh 174001, India
    Recruiting
  • Atal Institute of Medical Super Specilities, (AIMSS) Chamiana
    Shimla, Himachal Pradesh 171001, India
    Recruiting
  • Manipal Hospital
    Bangalore, Karnataka 560017, India
    Not yet recruiting
  • Sparsh Superspeciality Hospital
    Bangalore, Karnataka 560022, India
    Recruiting
    • Madhusudhan B Kempegowda, MD DM · Contactdrmadhubk@gmail.com · 9902078244
    • Madhusudhan B Kempegowda, MD DM · Principal investigator
  • National Institute of Mental Health and Neuro-Sciences
    Bangalore, Karnataka 560029, India
    Not yet recruiting
    • Girish B Kulkarni, MD DM · Contactgbk5000@rediffmail.com · 9035160614
    • Girish B Kulkarni, MD DM · Principal investigator
  • KLE's Dr. Prabhakar Kore Hospital & Medical Research Centre
    Belagavi, Karnataka 590010, India
    Recruiting
    • Aralikatte O Saroja, MD DM · Contactsarojaao2002@yahoo.com · 9448468474
    • Aralikatte O Saroja, MD DM · Principal investigator
  • Kasturba Medical College Manipal
    Manipal, Karnataka 576104, India
    Recruiting
    • Girish Menon, MBBS MCh · Contactgirish.menon@manipal.edu · 7760563666
    • Girish Menon, MBBS MCh · Principal investigator
  • Baby Memorial Hospital
    Calicut, Kerala 673004, India
    Recruiting
    • Ummer Karadan, MD DM · Contactummerneuro1@gmail.com · 94478 43954
    • Ummer Karadan, MD DM · Principal investigator
  • ASTER MIMS Hospital
    Calicut, Kerala 673016, India
    Recruiting
    • Paul J Alapatt, DM, PDF · Contactpauljalapatt@gmail.com · 9447342034
    • Paul J Alapatt, DM, PDF · Principal investigator
  • Amrita Institute for Medical Sciences and Research Center
    Kochi, Kerala 682041, India
    Recruiting
  • Government Medical College Trivandrum
    Thiruvananthapuram, Kerala 695011, India
    Recruiting
  • Sree Chitra Tirunal Institute for Medical Sciences and Technology
    Thiruvananthapuram, Kerala 695011, India
    Recruiting
    • Padmavathyamma N Sylaja, MD DM · Contactsylajapn@hotmail.com · 9446566287
    • Padmavathyamma N Sylaja, MD DM · Principal investigator
  • Fortis Hospital Mulund
    Mumbai, Maharashtra 400078, India
    Recruiting
    • Rajesh Benny, DNB DM · Contactrajeshbenny@gmail.com · 9820410322
    • Rajesh Benny, DNB DM · Principal investigator
  • Holy Spirit Hospital
    Mumbai, Maharashtra 400093, India
    Recruiting
    • Darshan Doshi, MD DM · Contactdarshankdoshi@gmail.com · 9845633469
    • Darshan Doshi, MD DM · Principal investigator
  • Ruby Hall Clinic
    Pune, Maharashtra 411001, India
    Recruiting
    • Kapil Zirpe, MBBS MD · Contactkapilzirpe@gmail.com · 9822844212
    • Kapil Zirpe, MBBS MD · Principal investigator
  • Bharati Vidyapeeth DTU Medical College
    Pune, Maharashtra 411043, India
    Recruiting
    • Sankar P Gorthi, MD DM · Contactpgorthi2002@yahoo.com · 8800233991
    • Sankar P Gorthi, MD DM · Principal investigator
  • All India Institute of Medical Sciences
    New Delhi, National Capital Territory of Delhi 110029, India
    Recruiting
    • Rohit Bhatia, MD DM · Contactrohitbhatia71@yahoo.com · 98912 67417
    • Rohit Bhatia, MD DM · Principal investigator
  • Institute of Human Behaviour and Allied Sciences
    New Delhi, National Capital Territory of Delhi 110095, India
    Recruiting
    • Rajinder K Dhamija, MD DNB · Contactdirector@ihbas.org · 99908 86679
    • Rajinder K Dhamija, MD DNB · Principal investigator
  • All India Institute of Medical Sciences
    Bhubaneswar, Odisha 751019, India
    Recruiting
  • Guru Gobind Singh Medical College and Hospital
    Farīdkot, Punjab 151203, India
    Recruiting
    • Sulena Sulena, MD DM · Contactsulenasingh@yahoo.co.in · 7087907025
    • Sulena Sulena, MD DM · Principal investigator
  • Christian Medical College and Hospital, Ludhiana, Punjab
    Ludhiana, Punjab 141008, India
    Recruiting
  • PBM Hospital
    Bikaner, Rajasthan 334001, India
    Recruiting
    • Inder Puri, MD DM · Contactdr.inderpuri@gmail.com · 7023266560
    • Inder Puri, MD DM · Principal investigator
  • Santokba Durlabhji Memorial Hospital
    Jaipur, Rajasthan 302015, India
    Recruiting
  • Fortis Escorts Hospital
    Jaipur, Rajasthan 302017, India
    Recruiting
    • Neetu Ramrakhiani, MD DM DNB · Contactneetudilip@yahoo.co.in · 9314932648
    • Neetu Ramrakhiani, MD DM DNB · Principal investigator
  • Dr. Kamakshi Memorial Hospital
    Chennai, Tamil Nadu 600100, India
    Recruiting
    • Parveen Chander, MD DM · Contactdrnpcmd@gmail.com · 9444472722
    • Parveen Chander, MD DM · Principal investigator
  • KG Hospital and Post Graduate Medical Institute Coimbatore
    Coimbatore, Tamil Nadu 641018, India
    Recruiting
    • TCR Ramakrishnan, MD DM · Contactkgneuro@gmail.com · 9443365792
    • TCR Ramakrishnan, MD DM · Principal investigator
  • Jawaharlal Institute of Postgraduate Medical Education and Research
    Puducherry, Tamil Nadu 605006, India
    Recruiting
    • Sunil K Narayan, DM, PhD · Contactsknarayan@gmail.com · 9443617120
    • Sunil K Narayan, DM, PhD · Principal investigator
  • Tirunelveli Medical College
    Tirunelveli, Tamil Nadu 627011, India
    Recruiting
  • Christian Medical College Vellore
    Vellore, Tamil Nadu 632517, India
    Recruiting
  • CARE Hospitals
    Hyderabad, Telangana Hyderabad, India
    Recruiting
    • Yerasu M Reddy, DM DNB · Contactmuralidharnims@gmail.com · 9912329342
    • Yerasu M Reddy, DM DNB · Principal investigator
  • King George's Medical University
    Lucknow, Uttar Pradesh 226003, India
    Recruiting
    • Parveen K Sharma, MD DM · Contactpspgimer@gmail.com · 7388111289
    • Parveen K Sharma, MD DM · Principal investigator
  • Institute of Medical Sciences of the Banaras Hindu University (BHU)
    Varanasi, Uttar Pradesh 221005, India
    Recruiting
  • Institute of Neurosciences
    Kolkata, West Bengal 700017, India
    Recruiting
    • Jayanta Roy, MD DM · Contactjroyneuro01@gmail.com · 9903048154
    • Jayanta Roy, MD DM · Principal investigator
  • Bangur Institute of Neurosciences
    Kolkata, West Bengal 700020, India
    Recruiting
  • The Calcutta Medical Research Center
    Kolkata, West Bengal 700027, India
    Recruiting
    • Sujoy Mukherjee, MD FNB · Contactdrsujoym@gmail.com · 9330960230
    • Sujoy Mukherjee, MD FNB · Principal investigator
  • Postgraduate Institute for Medical Education and Research
    Chandigarh, 160012, India
    Recruiting
    • Dheeraj Khurana, MD DM · Contactdherajk@yahoo.com · 7087009695
    • Dheeraj Khurana, MD DM · Principal investigator
  • St Stephen's Hospital
    Delhi, 110054, India
    Recruiting
    • Gaurav K Mittal, MD DM · Contactdrgkmittal@gmail.com · 7042877975
    • Gaurav K Mittal, MD DM · Principal investigator
08

References and documents

Publications

  • Sprigg N, Flaherty K, Appleton JP, Al-Shahi Salman R, Bereczki D, Beridze M, Christensen H, Ciccone A, Collins R, Czlonkowska A, Dineen RA, Duley L, Egea-Guerrero JJ, England TJ, Krishnan K, Laska AC, Law ZK, Ozturk S, Pocock SJ, Roberts I, Robinson TG, Roffe C, Seiffge D, Scutt P, Thanabalan J, Werring D, Whynes D, Bath PM; TICH-2 Investigators. Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial. Lancet. 2018 May 26;391(10135):2107-2115. doi: 10.1016/S0140-6736(18)31033-X. Epub 2018 May 16. PubMed 29778325 ↗
  • Meretoja A, Churilov L, Campbell BC, Aviv RI, Yassi N, Barras C, Mitchell P, Yan B, Nandurkar H, Bladin C, Wijeratne T, Spratt NJ, Jannes J, Sturm J, Rupasinghe J, Zavala J, Lee A, Kleinig T, Markus R, Delcourt C, Mahant N, Parsons MW, Levi C, Anderson CS, Donnan GA, Davis SM. The spot sign and tranexamic acid on preventing ICH growth--AUStralasia Trial (STOP-AUST): protocol of a phase II randomized, placebo-controlled, double-blind, multicenter trial. Int J Stroke. 2014 Jun;9(4):519-24. doi: 10.1111/ijs.12132. Epub 2013 Aug 26. PubMed 23981692 ↗
  • Pandian JD, Phillips A, Verma SJ, Arora D, Dhasan A, Raju PS, Sylaja PN, Ray BK, Chakraborty U, Johnson J, Sharma PK, Bhoi S, Jha M, Iype T, P C, Khurana D, Ray S, Das D, Kalita N, Adhikari S, Sharma A, Roy J, Sahonta R, Singh S, Chaudhary V, Menon G, Aaron S, Bal D, Dhamija RK, Chaturvedi M, Maheshwari S, Saroja AO, Naik KR, Bhutani N, Dhankhar K, Sharma D, Bhatia R, Gorthi SP, Sarmah B, Pamidimukkala V, Saravanan S, Narayan S, Basumatary LJ, Sundarachary NV, Upputuri AK, Karadan U, Pradeep Kumar VG, Parthasarathy R, Doshi D, Wagh S, Ramakrishnan T, Akhtar S, Desai S, Borah NC, Das R, Mittal G, Jain A, Alapatt PJ, Kulkarni GB, Menon D, Raja P, Puri I, Nambiar V, Yerasu MR, Jaiswal SK, Zirpe K, Gurav S, Sharma S, Kumaravelu S, Benny R, Thakkar V, Pathak A, Kempegowda M, Chander P, Ramrakhiani N, Ks AD, Sarma PS, Huilgol R, Sharma M, Dhaliwal RS. Indian Trial of Tranexamic acid in Spontaneous Intracerebral Hemorrhage study protocol. Int J Stroke. 2025 Jul;20(6):756-762. doi: 10.1177/17474930241307933. Epub 2025 Jan 3. PubMed 39633570 ↗

Individual participant data

Plan to share: No — All information collected from medical records for the study will be stored electronically in a specifically designed database at the Christian Medical College and Hospital, Ludhiana, Punjab, India. Participants information will be identified only by their initials and a study registration number. Any information transferred electronically will be coded to protect confidentiality. All computer records will be password-protected. The study results may be presented at conferences or in scientific publications, but individual participants will not be identifiable. If needed, data will be available in future for other researchers outside the primary research group for secondary purposes, such as meta-analyses, reanalysis, or replication of results.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2022 (actual). Primary completion is estimated for Nov 2026, 51 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2023
First posted
May 1, 2023
StartActual
Aug 30, 2022
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2026
Last update
Jan 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05836831
Lead sponsor
Christian Medical College and Hospital, Ludhiana, India
Collaborators
Indian Council of Medical Research, Sree Chitra Tirunal Institute for Medical Sciences & Technology, Post Graduate Institute of Medical Education and Research, Chandigarh, St. Stephen's Hospital, Delhi, All India Institute of Medical Sciences, Amrita Institute of Medical Sciences & Research Center, Kasturba Medical College Manipal, India, Institute of Neurosciences Kolkata, Bangur Institute of Neurosciences Kolkata, India, Guwahati Neurological Research Center, Guwahati, India, Baptist Christian Hospital, Tezpur, India, National Institute of Mental Health and Neuro Sciences, India, Jawaharlal Institute of Postgraduate Medical Education & Research, Christian Medical College, Vellore, India, CARE Hospitals Hyderabad, India, Lalitha Super Specialities Hospital Guntur, India, Dr. Ramesh Cardiac and Multispeciality Hospital Guntur, India, Government General Hospital Guntur, India, Fortis Escorts Hospital Jaipur, India, Institute of Medical Sciences of the Banaras Hindu University, India, Atal Institute of Medical Super Specilities, (AIMSS) Chamiana, Shimla, All India Institute of Medical Sciences, Bhubaneswar, KLEs Dr. Prabhakar Kore Hospital & Medical Research Centre Balgaum, India, Guru Gobind Singh Medical College & Hospital, PBM Hospital Bikaner, India, Shree Krishna Hospital Pramukhswami Medical College Anand, India, Apollo Excelcare Hospitals Guwahati, India, Manipal Hospital Bangalore, India, Artemis Hospital Gurgaon, India, Dr. Kamakshi Memorial Hospital Chennai, India, Bharati Vidyapeeth DTU Medical College Pune, India, Aster MIMS Hospital Calicut, India, Holy Spirit Hospital Mumbai, India, Sparsh Superspeciality Hospital Bangalore, India, King George's Medical University, Lucknow, India, Assam Medical College, Dibrugarh, India, KG Hospital and Post Graduate Medical Institute Coimbatore, India, Tirunelveli Medical College, Tirunelveli, India, Santokba Durlabhji Memorial Hospital, Jaipur, India, Tezpur Medical College and Hospital, Assam, India, Baby Memorial Hospital Calicut, India, Institute of Human Behaviour and Allied Sciences Delhi, India, The Calcutta Medical Research Institute, Kolkata, India, Fortis Hospital Mulund Mumbai, India, Government Medical College Trivandrum, India, Ruby Hall Clinic, Pune, India, Manipal Hospital Goa, India
Responsible party
Jeyaraj D Pandian (Principal and Professor, Department of Neurology, Christian Medical College and Hospital, Ludhiana, India) — Principal investigator
First posted
May 1, 2023
Start date
Aug 30, 2022
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Jan 22, 2026

Study contacts

Jeyaraj D Pandian, MD DM
Contact
jeyarajpandian@hotmail.com
9915784750
Atul Phillips, MD FNB
Contact
atulphillips@yahoo.co.in
9999464983
Jeyaraj D Pandian, MD DM
principal investigator · Christian Medical College and Hospital, Ludhiana, Punjab, India

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tranexamic Acid

Start the discussion